{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T14:10:58Z","timestamp":1777558258513,"version":"3.51.4"},"reference-count":65,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100004694","name":"Kaohsiung Medical University","doi-asserted-by":"publisher","award":["KMU-DK109002-4"],"award-info":[{"award-number":["KMU-DK109002-4"]}],"id":[{"id":"10.13039\/501100004694","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004663","name":"Ministry of Science and Technology, Taiwan","doi-asserted-by":"publisher","award":["110\\u20132320-B-037\\u2013011-MY3"],"award-info":[{"award-number":["110\\u20132320-B-037\\u2013011-MY3"]}],"id":[{"id":"10.13039\/501100004663","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical Pharmacology"],"published-print":{"date-parts":[[2022,8]]},"DOI":"10.1016\/j.bcp.2022.115152","type":"journal-article","created":{"date-parts":[[2022,6,22]],"date-time":"2022-06-22T11:03:42Z","timestamp":1655895822000},"page":"115152","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["Discovery of 7, 4\u2032-dimethoxy-3-hydroxyflavone as a protease-activated receptor 4 antagonist with antithrombotic activity and less bleeding tendency in mice"],"prefix":"10.1016","volume":"202","author":[{"given":"Ying-Ting","family":"Lin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hui-Ching","family":"Hsu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ju-Ying","family":"Tsai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jia-Hau","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chi-Jung","family":"Tai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ming-Jung","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chin-Chung","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"9215","key":"10.1016\/j.bcp.2022.115152_b0005","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1016\/S0140-6736(00)02225-X","article-title":"Blood coagulation","volume":"355","author":"Dahlback","year":"2000","journal-title":"Lancet"},{"key":"10.1016\/j.bcp.2022.115152_b0010","doi-asserted-by":"crossref","DOI":"10.1016\/j.blre.2020.100733","article-title":"Interplay between platelets and coagulation","volume":"46","author":"Sang","year":"2021","journal-title":"Blood Rev."},{"issue":"4","key":"10.1016\/j.bcp.2022.115152_b0015","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1038\/s41569-019-0314-y","article-title":"Dual-pathway inhibition for secondary and tertiary antithrombotic prevention in cardiovascular disease","volume":"17","author":"Capodanno","year":"2020","journal-title":"Nat. Rev. Cardiol."},{"issue":"6","key":"10.1016\/j.bcp.2022.115152_b0020","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1177\/1074248415578172","article-title":"Effects of rivaroxaban on platelet activation and platelet-coagulation pathway interaction: In vitro and in vivo studies","volume":"20","author":"Perzborn","year":"2015","journal-title":"J. Cardiovasc. Pharmacol. Ther."},{"issue":"8","key":"10.1016\/j.bcp.2022.115152_b0025","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1111\/j.1538-7836.2005.01377.x","article-title":"Protease-activated receptors in hemostasis, thrombosis and vascular biology","volume":"3","author":"Coughlin","year":"2005","journal-title":"J. Thromb. Haemost."},{"issue":"20","key":"10.1016\/j.bcp.2022.115152_b0030","doi-asserted-by":"crossref","first-page":"2952","DOI":"10.1111\/bph.13455","article-title":"Protease-activated receptor 4: from structure to function and back again","volume":"173","author":"French","year":"2016","journal-title":"Br. J. Pharmacol."},{"issue":"8","key":"10.1016\/j.bcp.2022.115152_b0035","doi-asserted-by":"crossref","first-page":"2697","DOI":"10.1111\/febs.15829","article-title":"Molecular mechanisms regulating Proteinase-Activated Receptors (PARs)","volume":"288","author":"Chandrabalan","year":"2021","journal-title":"FEBS J."},{"issue":"33","key":"10.1016\/j.bcp.2022.115152_b0040","doi-asserted-by":"crossref","first-page":"25216","DOI":"10.1074\/jbc.M004589200","article-title":"Protease-activated receptors 1 and 4 are shut off with distinct kinetics after activation by thrombin","volume":"275","author":"Shapiro","year":"2000","journal-title":"J. Biol. Chem."},{"issue":"4","key":"10.1016\/j.bcp.2022.115152_b0045","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1055\/s-0037-1613071","article-title":"Role of the PAR4 thrombin receptor in stabilizing platelet-platelet aggregates as revealed by a patient with Hermansky-Pudlak syndrome","volume":"87","author":"Covic","year":"2002","journal-title":"Thromb. Haemost."},{"issue":"2","key":"10.1016\/j.bcp.2022.115152_b0050","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1160\/TH03-02-0103","article-title":"The role of PAR4 in thrombin-induced thromboxane production in human platelets","volume":"90","author":"Wu","year":"2003","journal-title":"Thromb. Haemost."},{"issue":"3","key":"10.1016\/j.bcp.2022.115152_b0055","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1111\/j.1476-5381.2010.00921.x","article-title":"The roles and mechanisms of PAR4 and P2Y12\/phosphatidylinositol 3-kinase pathway in maintaining thrombin-induced platelet aggregation","volume":"161","author":"Wu","year":"2010","journal-title":"Br. J. Pharmacol."},{"issue":"8","key":"10.1016\/j.bcp.2022.115152_b0060","doi-asserted-by":"crossref","first-page":"1642","DOI":"10.1111\/jth.13293","article-title":"Inhibition of protease-activated receptor 4 impairs platelet procoagulant activity during thrombus formation in human blood","volume":"14","author":"French","year":"2016","journal-title":"J. Thromb. Haemost."},{"issue":"5","key":"10.1016\/j.bcp.2022.115152_b0065","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1161\/01.ATV.0000014742.56572.25","article-title":"PAR-4 agonist AYPGKF stimulates thromboxane production by human platelets","volume":"22","author":"Henriksen","year":"2002","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"issue":"1","key":"10.1016\/j.bcp.2022.115152_b0070","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1111\/jth.14643","article-title":"Molecular basis of protease-activated receptor 1 signaling diversity","volume":"18","author":"Willis Fox","year":"2020","journal-title":"J. Thromb. Haemost."},{"issue":"7","key":"10.1016\/j.bcp.2022.115152_b0075","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1007\/s40265-015-0387-9","article-title":"Vorapaxar: a review of its use in the long-term secondary prevention of atherothrombotic events","volume":"75","author":"Frampton","year":"2015","journal-title":"Drugs"},{"issue":"8","key":"10.1016\/j.bcp.2022.115152_b0080","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1111\/jth.12619","article-title":"Targeting the anionic region of human protease-activated receptor 4 inhibits platelet aggregation and thrombosis without interfering with hemostasis","volume":"12","author":"Mumaw","year":"2014","journal-title":"J. Thromb. Haemost."},{"issue":"371","key":"10.1016\/j.bcp.2022.115152_b0085","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaf5294","article-title":"Blockade of protease-activated receptor-4 (PAR4) provides robust antithrombotic activity with low bleeding","volume":"9","author":"Wong","year":"2017","journal-title":"Sci. Transl. Med."},{"issue":"11","key":"10.1016\/j.bcp.2022.115152_b0090","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1160\/TH17-03-0219","article-title":"Protease-activated receptor PAR-4: an inducible switch between thrombosis and vascular inflammation?","volume":"117","author":"Fender","year":"2017","journal-title":"Thromb. Haemost."},{"issue":"9","key":"10.1016\/j.bcp.2022.115152_b0095","doi-asserted-by":"crossref","first-page":"3176","DOI":"10.1182\/blood-2007-02-075440","article-title":"Protease-activated receptor-4 inhibition protects from multiorgan failure in a murine model of systemic inflammation","volume":"110","author":"Slofstra","year":"2007","journal-title":"Blood"},{"issue":"19","key":"10.1016\/j.bcp.2022.115152_b0100","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1161\/CIRCULATIONAHA.113.007590","article-title":"Thrombin receptor protease-activated receptor 4 is a key regulator of exaggerated intimal thickening in diabetes mellitus","volume":"130","author":"Pavic","year":"2014","journal-title":"Circulation"},{"key":"10.1016\/j.bcp.2022.115152_b0105","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112893","article-title":"Protease activated receptor 4 (PAR4) antagonists: Research progress on small molecules in the field of antiplatelet agents","volume":"209","author":"Liu","year":"2021","journal-title":"Eur. J. Med. Chem."},{"issue":"2","key":"10.1016\/j.bcp.2022.115152_b0110","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1038\/nrd4510","article-title":"The re-emergence of natural products for drug discovery in the genomics era","volume":"14","author":"Harvey","year":"2015","journal-title":"Nature reviews. Drug Discov"},{"key":"10.1016\/j.bcp.2022.115152_b0115","unstructured":"A.G. Atanasov, S.B. Zotchev, V.M. Dirsch, T., C.T. Supuran. International Natural Product Sciences, Natural products in drug discovery: advances and opportunities, Nature reviews. Drug Discov 20(3) (2021) 200-216."},{"issue":"3","key":"10.1016\/j.bcp.2022.115152_b0120","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1021\/acs.jnatprod.9b01285","article-title":"Natural products as sources of new drugs over the nearly four decades from 01\/1981 to 09\/2019","volume":"83","author":"Newman","year":"2020","journal-title":"J. Nat. Prod."},{"issue":"4","key":"10.1016\/j.bcp.2022.115152_b0125","doi-asserted-by":"crossref","first-page":"293","DOI":"10.2174\/1389201020666190328115411","article-title":"Computer-assisted drug virtual screening based on the natural product databases","volume":"20","author":"Yang","year":"2019","journal-title":"Curr. Pharm. Biotechnol."},{"issue":"9","key":"10.1016\/j.bcp.2022.115152_b0130","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.1007\/s12272-015-0640-5","article-title":"Role of computer-aided drug design in modern drug discovery","volume":"38","author":"Macalino","year":"2015","journal-title":"Arch Pharm Res"},{"issue":"25","key":"10.1016\/j.bcp.2022.115152_b0135","doi-asserted-by":"crossref","first-page":"6144","DOI":"10.1021\/jm049654z","article-title":"A 3D similarity method for scaffold hopping from known drugs or natural ligands to new chemotypes","volume":"47","author":"Jenkins","year":"2004","journal-title":"J. Med. Chem."},{"issue":"6","key":"10.1016\/j.bcp.2022.115152_b0140","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1055\/s-0037-1613128","article-title":"Selective inhibition of protease-activated receptor 4-dependent platelet activation by YD-3","volume":"87","author":"Wu","year":"2002","journal-title":"Thromb. Haemost."},{"issue":"7","key":"10.1016\/j.bcp.2022.115152_b0145","doi-asserted-by":"crossref","first-page":"2466","DOI":"10.1021\/ja1005306","article-title":"ChemBioOffice Ultra 2010 suite","volume":"132","author":"Kerwin","year":"2010","journal-title":"J. Am. Chem. Soc."},{"issue":"7","key":"10.1016\/j.bcp.2022.115152_b0150","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1002\/(SICI)1096-987X(199905)20:7<730::AID-JCC8>3.0.CO;2-T","article-title":"MMFF VII. Characterization of MMFF94, MMFF94s, and other widely available force fields for conformational energies and for intermolecular-interaction energies and geometries","volume":"20","author":"Halgren","year":"1999","journal-title":"J. Comput. Chem."},{"issue":"6","key":"10.1016\/j.bcp.2022.115152_b0155","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/0898-5529(90)90162-2","article-title":"An alternative method for the alignment of molecular structures: Maximizing electrostatic and steric overlap","volume":"3","author":"Kearsley","year":"1990","journal-title":"Tetrahedron Comput. Method"},{"issue":"3","key":"10.1016\/j.bcp.2022.115152_b0160","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1016\/j.bmc.2007.10.070","article-title":"Synthesis and antiplatelet activity of ethyl 4-(1-benzyl-1H-indazol-3-yl)benzoate (YD-3) derivatives","volume":"16","author":"Chen","year":"2008","journal-title":"Bioorg. Med. Chem."},{"issue":"4","key":"10.1016\/j.bcp.2022.115152_b0165","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0062839","article-title":"Use of natural products as chemical library for drug discovery and network pharmacology","volume":"8","author":"Gu","year":"2013","journal-title":"PLoS ONE"},{"key":"10.1016\/j.bcp.2022.115152_b0170","doi-asserted-by":"crossref","DOI":"10.1016\/j.phymed.2020.153449","article-title":"Juglone prevents human platelet aggregation through inhibiting Akt and protein disulfide isomerase","volume":"82","author":"Kao","year":"2021","journal-title":"Phytomedicine"},{"issue":"4","key":"10.1016\/j.bcp.2022.115152_b0175","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1161\/ATVBAHA.118.311758","article-title":"Selective inhibition of PAR4 (Protease-Activated Receptor 4)-mediated platelet activation by a synthetic nonanticoagulant heparin analog","volume":"39","author":"Lin","year":"2019","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.bcp.2022.115152_b0180","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.redox.2017.05.019","article-title":"HPW-RX40 prevents human platelet activation by attenuating cell surface protein disulfide isomerases","volume":"13","author":"Kung","year":"2017","journal-title":"Redox Biol."},{"issue":"6","key":"10.1016\/j.bcp.2022.115152_b0185","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1038\/sj.bjp.0703437","article-title":"YD-3, a novel inhibitor of protease-induced platelet activation","volume":"130","author":"Wu","year":"2000","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.bcp.2022.115152_b0190","doi-asserted-by":"crossref","first-page":"42717","DOI":"10.1038\/srep42717","article-title":"SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules","volume":"7","author":"Daina","year":"2017","journal-title":"Sci. Rep."},{"issue":"17","key":"10.1016\/j.bcp.2022.115152_b0195","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1053\/euhj.2000.2515","article-title":"Platelet activation: assessment and quantification","volume":"22","author":"Kamath","year":"2001","journal-title":"Eur. Heart J."},{"issue":"4","key":"10.1016\/j.bcp.2022.115152_b0200","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1055\/s-0038-1675144","article-title":"Platelet signaling in primary haemostasis and arterial thrombus formation: Part 1","volume":"38","author":"Scharf","year":"2018","journal-title":"Hamostaseologie"},{"issue":"41","key":"10.1016\/j.bcp.2022.115152_b0205","doi-asserted-by":"crossref","first-page":"10948","DOI":"10.1073\/pnas.1707364114","article-title":"Complement-activation fragment C4a mediates effector functions by binding as untethered agonist to protease-activated receptors 1 and 4","volume":"114","author":"Wang","year":"2017","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1\u20133","key":"10.1016\/j.bcp.2022.115152_b0210","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.ejphar.2006.07.004","article-title":"Comparison of the effects of PAR1 antagonists, PAR4 antagonists, and their combinations on thrombin-induced human platelet activation","volume":"546","author":"Wu","year":"2006","journal-title":"Eur. J. Pharmacol."},{"issue":"8","key":"10.1016\/j.bcp.2022.115152_b0215","doi-asserted-by":"crossref","first-page":"2787","DOI":"10.1182\/blood-2002-03-0902","article-title":"Platelets, circulating tissue factor, and fibrin colocalize in ex vivo thrombi: real-time fluorescence images of thrombus formation and propagation under defined flow conditions","volume":"100","author":"Balasubramanian","year":"2002","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.bcp.2022.115152_b0220","doi-asserted-by":"crossref","first-page":"1632","DOI":"10.1161\/ATVBAHA.118.311112","article-title":"Genetic variant in human PAR (Protease-Activated Receptor) 4 enhances thrombus formation resulting in resistance to antiplatelet therapeutics","volume":"38","author":"Tourdot","year":"2018","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"issue":"19","key":"10.1016\/j.bcp.2022.115152_b0225","doi-asserted-by":"crossref","first-page":"4708","DOI":"10.1016\/j.bmcl.2014.08.021","article-title":"Substituted indoles as selective protease activated receptor 4 (PAR-4) antagonists: Discovery and SAR of ML354","volume":"24","author":"Wen","year":"2014","journal-title":"Bioorg. Med. Chem. Lett."},{"issue":"16","key":"10.1016\/j.bcp.2022.115152_b0230","doi-asserted-by":"crossref","first-page":"7690","DOI":"10.1021\/acs.jmedchem.6b00928","article-title":"Development of a series of (1-benzyl-3-(6-methoxypyrimidin-3-yl)-5-(trifluoromethoxy)-1H-indol-2-yl)methanol s as selective protease activated receptor 4 (PAR4) antagonists with in vivo utility and activity against gamma-thrombin","volume":"59","author":"Temple","year":"2016","journal-title":"J. Med. Chem."},{"issue":"6","key":"10.1016\/j.bcp.2022.115152_b0235","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0065528","article-title":"Synthesis of indole derived protease-activated receptor 4 antagonists and characterization in human platelets","volume":"8","author":"Young","year":"2013","journal-title":"PLoS ONE"},{"issue":"22","key":"10.1016\/j.bcp.2022.115152_b0240","doi-asserted-by":"crossref","first-page":"5481","DOI":"10.1016\/j.bmcl.2016.10.020","article-title":"Identification of the minimum PAR4 inhibitor pharmacophore and optimization of a series of 2-methoxy-6-arylimidazo[2,1-b][1,3,4]thiadiazoles","volume":"26","author":"Temple","year":"2016","journal-title":"Bioorg. Med. Chem. Lett."},{"issue":"16","key":"10.1016\/j.bcp.2022.115152_b0245","doi-asserted-by":"crossref","first-page":"7400","DOI":"10.1021\/acs.jmedchem.9b00186","article-title":"Discovery of potent protease-activated receptor 4 antagonists with in vivo antithrombotic efficacy","volume":"62","author":"Miller","year":"2019","journal-title":"J. Med. Chem."},{"issue":"11","key":"10.1016\/j.bcp.2022.115152_b0250","doi-asserted-by":"crossref","first-page":"3061","DOI":"10.1021\/jm800180e","article-title":"Discovery of a novel, orally active himbacine-based thrombin receptor antagonist (SCH 530348) with potent antiplatelet activity","volume":"51","author":"Chackalamannil","year":"2008","journal-title":"J. Med. Chem."},{"issue":"1","key":"10.1016\/j.bcp.2022.115152_b0255","doi-asserted-by":"crossref","first-page":"6144","DOI":"10.1038\/s41598-018-24284-4","article-title":"Measurement of metabolite variations and analysis of related gene expression in Chinese liquorice (Glycyrrhiza uralensis) plants under UV-B irradiation","volume":"8","author":"Zhang","year":"2018","journal-title":"Sci. Rep."},{"issue":"6","key":"10.1016\/j.bcp.2022.115152_b0260","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1016\/j.fitote.2010.01.009","article-title":"Fuscacarpans A-C, new pterocarpans from the stems of Erythrina fusca","volume":"81","author":"Innok","year":"2010","journal-title":"Fitoterapia"},{"issue":"12","key":"10.1016\/j.bcp.2022.115152_b0265","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1038\/sj.ejcn.1602022","article-title":"Intake of specific flavonoid classes and coronary heart disease\u2013a case-control study in Greece","volume":"58","author":"Lagiou","year":"2004","journal-title":"Eur. J. Clin. Nutr."},{"issue":"3","key":"10.1016\/j.bcp.2022.115152_b0270","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1079\/PHN2006859","article-title":"Intake of specific flavonoids and risk of acute myocardial infarction in Italy","volume":"9","author":"Tavani","year":"2006","journal-title":"Public Health Nutr."},{"key":"10.1016\/j.bcp.2022.115152_b0275","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.fct.2018.02.014","article-title":"Evidence and prospective of plant derived flavonoids as antiplatelet agents: Strong candidates to be drugs of future","volume":"119","author":"Khan","year":"2018","journal-title":"Food Chem. Toxicol."},{"issue":"1","key":"10.1016\/j.bcp.2022.115152_b0280","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1111\/bcp.12923","article-title":"Antioxidant and antiplatelet activity by polyphenol-rich nutrients: focus on extra virgin olive oil and cocoa","volume":"83","author":"Loffredo","year":"2017","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.bcp.2022.115152_b0285","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.ejphar.2017.04.009","article-title":"Flavonoids and platelet aggregation: A brief review","volume":"807","author":"Faggio","year":"2017","journal-title":"Eur. J. Pharmacol."},{"issue":"6","key":"10.1016\/j.bcp.2022.115152_b0290","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1111\/j.1476-5381.2009.00440.x","article-title":"Differential effects of quercetin, apigenin and genistein on signalling pathways of protease-activated receptors PAR(1) and PAR(4) in platelets","volume":"158","author":"Navarro-Nunez","year":"2009","journal-title":"Br. J. Pharmacol."},{"issue":"2","key":"10.1016\/j.bcp.2022.115152_b0295","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1111\/j.1538-7836.2004.01099.x","article-title":"Flavonoids inhibit platelet function through binding to the thromboxane A2 receptor","volume":"3","author":"Guerrero","year":"2005","journal-title":"J. Thromb. Haemost."},{"issue":"3","key":"10.1016\/j.bcp.2022.115152_b0300","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1160\/TH13-01-0014","article-title":"12-lipoxygenase activity plays an important role in PAR4 and GPVI-mediated platelet reactivity","volume":"110","author":"Yeung","year":"2013","journal-title":"Thromb. Haemost."},{"issue":"4","key":"10.1016\/j.bcp.2022.115152_b0305","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1046\/j.1538-7836.2003.00138.x","article-title":"Thrombin-induced platelet PAR4 activation: role of glycoprotein Ib and ADP","volume":"1","author":"Adam","year":"2003","journal-title":"J. Thromb. Haemost."},{"issue":"23","key":"10.1016\/j.bcp.2022.115152_b0310","doi-asserted-by":"crossref","DOI":"10.21037\/atm.2017.09.10","article-title":"Drugs targeting protease-activated receptor-4 improve the anti-thrombotic therapeutic window","volume":"5","author":"French","year":"2017","journal-title":"Ann. Transl. Med."},{"issue":"2","key":"10.1016\/j.bcp.2022.115152_b0315","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1161\/ATVBAHA.117.310550","article-title":"PAR4 (Protease-Activated Receptor 4): PARticularly Important 4 Antiplatelet Therapy","volume":"38","author":"Han","year":"2018","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"issue":"3","key":"10.1016\/j.bcp.2022.115152_b0320","doi-asserted-by":"crossref","first-page":"56","DOI":"10.21037\/atm.2017.11.36","article-title":"Protease activated receptor 4: a backup receptor or a dark horse as a target in antiplatelet therapy?","volume":"6","author":"Han","year":"2018","journal-title":"Ann. Transl. Med."},{"issue":"1\u20132","key":"10.1016\/j.bcp.2022.115152_b0325","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.thromres.2004.07.009","article-title":"An optimized murine model of ferric chloride-induced arterial thrombosis for thrombosis research","volume":"115","author":"Wang","year":"2005","journal-title":"Thromb. Res."}],"container-title":["Biochemical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295222002465?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295222002465?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T18:21:47Z","timestamp":1777400507000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006295222002465"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8]]},"references-count":65,"alternative-id":["S0006295222002465"],"URL":"https:\/\/doi.org\/10.1016\/j.bcp.2022.115152","relation":{},"ISSN":["0006-2952"],"issn-type":[{"value":"0006-2952","type":"print"}],"subject":[],"published":{"date-parts":[[2022,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Discovery of 7, 4\u2032-dimethoxy-3-hydroxyflavone as a protease-activated receptor 4 antagonist with antithrombotic activity and less bleeding tendency in mice","name":"articletitle","label":"Article Title"},{"value":"Biochemical Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bcp.2022.115152","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"115152"}}